In a report released today, Emily Field from Barclays maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF250.00. The company’s shares opened today at $237.81.
According to TipRanks, Field is ranked #5805 out of 8753 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $272.07 average price target.
The company has a one-year high of $323.78 and a one-year low of $240.32. Currently, Roche Holding AG has an average volume of 5,827.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- Roche receives FDA approval for molecular test to screen blood donors for malaria
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Immunovant rallies after Chugai myasthenia gravis study failure
